...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Serum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Non-small Cell Lung Cancer Before and after Intervention
【24h】

Serum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Non-small Cell Lung Cancer Before and after Intervention

机译:血清肿瘤标志物,缺氧诱导因子-1αHIF-1α和血管内皮生长因子,介入前后非小细胞肺癌患者

获取原文
           

摘要

Objective: To explore changes in the serum tumor makers, hypoxia-inducible factor- (HIF- ) and vascular endothelial growth factor (VEGF) level and their relations in patients with non-small cell lung cancer (NSCLC) before and after intervention. Materials and Methods: Forty patients with NSCLC and 40 healthy individuals undergoing physical examination in our hospital provided the observation and control groups. HIF- and VEGF levels in serum were detected by enzyme-linked immuno-sorbent assay (ELISA) in the observation group before and after intervention and in control group on the day of physical examination, along with serum carcino-embryonic antigen (CEA), neuron-speci ic enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group with a fully automatic biochemical analyzer. Clinical effects and improvement of life quality in the observation group were also evaluated. Results: The total effective rate and improvement of life quality after treatment in observation group were 30.0% and 32.5%, respectively. Serum HIF- and VEGF levels in the control group were lower than that in observation group (p demonstrated a positive relation with VEGF level (p and VEGF levels and decrease of indexes related to hematological tumor markers in NSCLC patients after intervention.
机译:目的:探讨血清肿瘤制造商,缺氧诱导因子 - (HIF-)和血管内皮生长因子(VEGF)水平的变化及干预前后非小细胞肺癌(NSCLC)的关系。材料和方法:在医院进行体检的40例NSCLC和40名健康个体患者提供了观察和对照组。在体检日之前和对照组之前和对照组之前和治疗组中的酶联免疫吸附剂测定(ELISA)检测血清中的HIF和VEGF水平,以及血清癌 - 胚胎抗原(CEA),具有全自动生物化学分析仪的观察组中的神经元 - 特异性IC烯醇酶(NSE)和鳞状细胞癌抗原(SCC)水平。还评估了观察组临床效果和改善观察组。结果:观察组治疗后的寿命率和改善寿命分别为30.0%和32.5%。对照组中的血清HIF和VEGF水平低于观察组中的血清HIF水平(P展示与VEGF水平的阳性关系(P和VEGF水平,干预后NSCLC患者的血液肿瘤标志物有关的指标。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号